Biomedical engineer Leyla Soleymani’s team was responsible for the hardware, including the chip that reads the sample.
Researchers at McMaster and Brock universities have created the prototype for a hand-held device to measure a biomarker for cancer, paving the way for home-based cancer monitoring and to improve access to diagnostic testing.
The device works much like the monitors that people with diabetes use to test their blood-sugar levels and could be used in a medical clinic or at home, all without lab work, greatly simplifying the process for testing blood for cancer’s signature.
A user would mix a droplet of blood in a vial of reactive liquid, then place the mixture onto a strip and insert it into a reader. In minutes, the device would measure an antigen that indicates the degree to which cancer is present.
The prototype has been designed to monitor prostate specific antigen (PSA) and the technology can readily be adapted to measure other markers, depending on the form of cancer or other chronic disease.
The ability to collect such information at home would make the daily lives of patients much easier while also generating accurate, shareable, up-to-the-minute results to guide their doctors in shaping care and treatment – all at a lower cost to the health-care system.
The device would also allow patients to continue to monitor their health after treatment.
The prototype was created by a research collaboration led by McMaster’s Leyla Soleymani, a biomedical engineer and Canada Research Chair in Miniaturized Biomedical Devices, and Brock’s Feng Li, an associate professor of chemistry who leads a bioanalytical chemistry lab.
Soleymani’s team (also including Sarah Traynor and Richa Pandey) was responsible for the hardware, including the chip that reads the sample, while Li’s team (also including Guan Wang) created the technology that analyzes the sample.
“This is another step toward truly personalized medicine,” Soleymani says. “We’re getting away from centralized, lab-based equipment for this kind of testing.
“This would make monitoring much more accessible and cut down on the number of times patients need to leave home to provide blood samples.”
Once commercialized, this device will be a paradigm shift for cancer diagnosis and prognosis, Li says.
“Since this device is a lot more accessible and user-friendly than conventional technologies, patients will be more willing to use it, which can improve clinical outcomes and save lives.”
The researchers’ proof-of-concept work is described in an article published in the journal Angewandte Chemie. The invention will need to be tested more broadly before earning the regulatory approvals that would permit commercial manufacturing
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Digital biomarker to guide cancer therapy and predict response durationon April 30, 2021 at 5:30 am
Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient's tumor ...
- Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Researchon April 30, 2021 at 4:19 am
Research and development growth to drive the growth of Global Cancer Biopsy Market in the forecast period 2022 2026 According to TechSci Research report Global Cancer Biopsy Market By Product ...
- WIN's Digital Display Precision Predictor biomarker to guide cancer targeted therapy & predict response durationon April 30, 2021 at 1:20 am
Width='300' Height='265'/> WIN Consortium announces publication of the Digital Display Precision Predictor global biomarker prototype for cancer pa ...
- WIN's DDPP biomarker to guide cancer therapy and predict response durationon April 29, 2021 at 9:00 pm
The Worldwide Innovative Network - WIN Consortium in personalized cancer medicine announces the publication in NPJ Precision Oncology of the Digital Display Precision Predictor (DDPP) global biomarker ...
- Amid a surge of targeted cancer meds, AstraZeneca, Amgen and Roche lead team promoting biomarker testingon April 29, 2021 at 6:15 am
AstraZeneca, Amgen and Roche’s Genentech are pushing biomarker testing awareness in an effort coordinated by the LUNGevity Foundation. The campaign rallies 18 different pharma partners including ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Cancer biomarker detector
- Study Shows Guardant Reveal Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivityon April 30, 2021 at 5:05 am
The single-center, prospective study evaluated the effectiveness of the Guardant Reveal liquid biopsy test to detect MRD in patients with stage I-IV colorectal cancer after curative intent therapy. ...
- Novel platform has potential to detect many disease-related biomarkers in just one teston April 27, 2021 at 9:46 pm
Most conventional molecular diagnostics usually detect only a single disease-related biomarker. Great examples are the PCR tests currently used to diagnose COVID-19 by detecting a specific sequence ...
- Multiplex Biomarker Imaging Market: Rising demand…on April 27, 2021 at 3:30 am
The global multiplex biomarker imaging market was valued US$ 300 Mn in 2018, and is expected to increase at a CAGR of 12% over the forecast period of 2019–2029.The growing incidence of cancer globally ...
- New prostate cancer urine test shows how aggressive disease ison April 27, 2021 at 12:30 am
Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is. A new study published today shows how an experimental ...
- Global Molecular Biomarkers for Cancer Detection and Management Market Size, Share, Value, and Competitive Landscape forecast year 2021-2026on April 22, 2021 at 11:37 pm
The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market ...